A method of in vivo assembly of a recombinant micelle including: introducing a plasmid into a plant cell, wherein: the plasmid includes a segment of deoxyribonucleic acid (DNA) for encoding a ribonucleic acid (RNA) for a protein in a casein micelle, the segment of DNA is transcribed and translated; forming recombinant casein proteins in the plant cell, wherein: the recombinant casein proteins include a κ-casein and at least one of an αS.sub.1-casein, an αS.sub.2-casein, a β-casein; and assembling in vivo a recombinant micelle within the plant cell, wherein: an outer layer of the recombinant micelle is enriched with the κ-casein, an inner matrix of the recombinant micelle include at least one of the αS.sub.1-casein, the αS.sub.2-casein, the β-casein.

The disclosure relates to systems and methods for improving the manufacturing of silk solutions and powders containing silk fibroin obtained from silkworm cocoons. The solutions and powders can be used to improve the post-harvest preservation of perishables and to improve the performance of packaging, including biodegradable packaging.

A treatment system for performing a treatment on a patient may include a treatment fluid preparation device having a pump connected by a fluid channel to a reservoir of a source fluid, the pump conveying the source fluid from the reservoir, through a filter, and combining the source fluid with a concentrate by pumping the source fluid with the concentrate to form a treatment fluid in a batch container. The treatment fluid preparation device may have a controller that controls a heater, the pump, and a memory. The controller starts the heater to warm the treatment fluid in the batch container at a time that is responsive to the treatment time stored in the memory. The controller also detects a pressure property of the filter to determine its integrity and outputs an indication of a failed batch if the pressure property indicates the integrity of the filter is insufficient.

Apparatus for in-line liquid exchanging a biomolecule-containing liquid is provided. The apparatus comprises a means for mixing at least two liquids comprising a multiple inlet flow-controller, the means for mixing also comprising an outlet in fluid connection with a tangential flow filtration device configured in single-pass mode.

A method for concentrating a substance in a milk product, the method including the steps of: feeding the milk product from a tank to a filtering device, filtering the milk product into a permeate and a retentate: such that the substance is concentrated in the retentate, circulating a first part of the retentate over the filtering device, feeding a second part of the retentate to the tank, repeating the circulations to thereby gradually increase a concentration of the substance in the milk product, and stopping the repeating when the concentration of the substance in the milk product has reached a predetermined value.

A process for producing pure lactic acid from a whey by-product rich in lactose and minerals, for example delactosed why permeate or concentrated whey permeate, is described. The method comprises upstream steps of neutralising the whey by-product with a basic metal hydroxide to form a precipitate comprising calcium and phosphate, and separating the precipitate from the whey by-product to provide a clarified whey by-product. The clarified whey by-product is fermentated by a bacterium capable of bioconversion of lactose to lactic acid to provide a fermentation broth containing a lactic acid salt. In the downstream steps, the fermentation broth is acidified to release lactic acid from the lactic acid salt, precipitate from the broth produced by acidification is removed, and the acidified fermentation broth is treated to recover pure lactic acid by removal of residual salts, and water, and optionally protein. The process of the invention produces lactic acid having a purity of 80-98% and an isomeric purity of >98% L-lactic acid using a process that employs upstream removal of divalent salts by chemical precipitation, bacterial fermentation of the demineralised substrate, and minimum downstream processing of the fermentation broth. The methods of the invention may also be employed with milk permeates.

The present invention provides a method to isolate native tuber protein using a pretreatment of tuber processing water and diafiltration against a salt solution. This sequence of steps has the advantage that protein is stabilized during diafiltration, increasing process efficiency and protein quality and yield.

Disclosed is method for the purification of an oligosaccharide of interest from a fermentation broth, the method comprises providing a cell-free fermentation broth to a first filtration step using a nanofiltration membrane, thereby providing a filtrate which contains the oligosaccharide of interest; subjecting the filtrate to a second filtration step using a nanofiltration membrane, thereby providing a retentate which contains the oligosaccharide of interest; and removing salts from the retentate thereby providing a purified preparation of the oligosaccharide of interest.

A micro alternating tangential flow (microATF) perfusion filter includes a hollow cylinder having a proximal end and a distal end. The proximal end is connected in series to a permeate chamber, followed by a retentate chamber. The proximal end either (i) terminates in or at the permeate chamber, or (ii) terminates in or at the retentate chamber. The portion of the proximal end within the permeate chamber, in a case of (ii), possesses at least one opening allowing fluid communication between an inside of the hollow cylinder and the permeate chamber. The microATF perfusion filter further includes an inlet, positioned over the retentate chamber, for communication with a source of positive or negative pressure, and an outlet, positioned in a wall of the permeate chamber, which can be connected to a check valve, which, in turn, can be connected to a hydrophobic fluid vent filter.

The present invention relates to processes for obtaining a highly concentrated antibody solution. In particular, to processes for obtaining a highly concentrated therapeutic antibody solution that may be used for highly concentrated therapeutic antibody formulations, e.g. suitable for subcutaneous administration.